IDEAYA signs license agreement with Jiangsu Hengrui Pharma for drug targeting lung cancer

From Nasdaq: 2024-12-30 03:38:28

IDEAYA Biosciences, Inc. has signed an exclusive global license agreement with Jiangsu Hengrui Pharmaceuticals for antibody drug conjugate SHR-4849, targeting Small Cell Lung Cancer and Neuroendocrine Tumors. Hengrui Pharma stands to earn up to $1.045 billion in upfront payments, milestones, and royalties on sales outside Greater China. IDEAYA plans to file a US IND for SHR-4849 by the first half of 2025. The DLL3-targeting Topo-I-payload ADC has shown promising antitumor activity in preclinical studies and is currently in a Phase 1 clinical trial. IDEAYA aims to combine SHR-4849 with their PARG inhibitor IDE161 for effective clinical combinations. On Friday, IDYA closed at $25.16 on the Nasdaq.



Read more at Nasdaq: IDEAYA Signs License Agreement For ADC SHR-4849 With Jiangsu Hengrui Pharma